Bristol-Myers Squibb Co (BMY) Expected to Announce Earnings of $0.91 Per Share

Share on StockTwits

Analysts expect Bristol-Myers Squibb Co (NYSE:BMY) to post earnings per share of $0.91 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Bristol-Myers Squibb’s earnings. The highest EPS estimate is $0.93 and the lowest is $0.86. Bristol-Myers Squibb reported earnings of $0.75 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 21.3%. The firm is scheduled to issue its next earnings report before the market opens on Thursday, October 25th.

According to Zacks, analysts expect that Bristol-Myers Squibb will report full year earnings of $3.64 per share for the current year, with EPS estimates ranging from $3.60 to $3.67. For the next year, analysts anticipate that the company will post earnings of $3.94 per share, with EPS estimates ranging from $3.71 to $4.18. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Bristol-Myers Squibb.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.87 by $0.14. The company had revenue of $5.70 billion during the quarter, compared to analysts’ expectations of $5.48 billion. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The firm’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.74 EPS.

BMY has been the subject of several recent analyst reports. Barclays lifted their price target on Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Friday, October 12th. Credit Suisse Group set a $61.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, October 14th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 price target for the company in a report on Friday, October 5th. ValuEngine cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Friday. Finally, Jefferies Financial Group set a $58.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, July 15th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $63.13.

BMY traded down $1.68 during midday trading on Friday, hitting $54.30. The company’s stock had a trading volume of 14,981,405 shares, compared to its average volume of 6,835,098. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.40 and a quick ratio of 1.28. The stock has a market capitalization of $88.76 billion, a price-to-earnings ratio of 18.04, a price-to-earnings-growth ratio of 1.45 and a beta of 0.98. Bristol-Myers Squibb has a 52-week low of $49.96 and a 52-week high of $70.05.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 1st. Stockholders of record on Friday, October 5th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend is Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BMY. CSat Investment Advisory L.P. acquired a new position in Bristol-Myers Squibb during the 2nd quarter worth approximately $113,000. Landaas & Co. WI ADV acquired a new position in Bristol-Myers Squibb during the 2nd quarter worth approximately $131,000. Mount Yale Investment Advisors LLC acquired a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $179,000. Selective Wealth Management acquired a new position in Bristol-Myers Squibb during the 3rd quarter worth approximately $184,000. Finally, LFA Lugano Financial Advisors SA lifted its position in Bristol-Myers Squibb by 85.8% during the 3rd quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock worth $199,000 after acquiring an additional 1,481 shares in the last quarter. 72.32% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

See Also: Why do earnings reports matter?

Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply